Skip to main content
letter
. 2017 Dec 19;131(7):818–821. doi: 10.1182/blood-2017-10-811729

Figure 1.

Figure 1.

Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.